NPM1 and acute myeloid leukemia: Sulfasalazine, a broadly available medicine with low toxicity profile, can inhibit xCT expression [152, 153] and demonstrated promising antileukemic effect when combined with standard chemotherapy, especially in NPM1-mutated AML samples [152, 153], leading to phase 1/2 clinical trial in elderly patients with ND AML (NCT05580861).